CSL Behring

from Wikipedia, the free encyclopedia

CSL Behring , based in King of Prussia , in the US state of Pennsylvania, is a business unit of the Australian biopharmaceutical group CSL Limited (Commonwealth Serum Laboratories) and specializes in the manufacture of plasma products.

The CSL Behring business unit employs more than 25,000 people worldwide. The largest production and research location is in Marburg in Hesse , others in Kankakee in the US state of Illinois and in Bern in the Swiss canton of the same name. There are also agencies in 16 other countries. The main markets for drugs made from human blood plasma are the USA, Europe, Japan, Latin America and the Middle East .

Products

CSL Behring develops, produces and sells biotechnological products for the areas of coagulation disorders, intensive care medicine and immunoglobulins. In Germany, CSL Behring supplies patients with 21 different plasma-based drugs, a recombinant factor VIII preparation and a fibrinolytic.

CSL Behring GmbH (Germany)

Today's German subsidiary was founded in 1904 as Behringwerke AG by Nobel Prize winner Emil von Behring , and its products include serums and vaccines against infectious diseases. From 1946 the production of plasma products is added. In 1952, Hoechst took over the Behringwerke as a subsidiary.

In the mid-1990s, the Behring factories began to be divided up; the plasma division was spun off and merged with the Rhône-Poulenc subsidiary Armor to form the Centeon joint venture at the beginning of 1996 . When Hoechst and Rhône-Poulenc merged to form Aventis in 1999 , Centeon became the Aventis subsidiary, Aventis Behring . Since the company no longer fit in with the newly defined core business of Aventis, the sale to the Australian CSL-Holding was decided in December 2003 and completed in the first half of 2004. Under the CSL, Aventis Behring was immediately merged with ZLB Bioplasma to form ZLB Behring . At the end of 2006 the abbreviation ZLB in the names of the subsidiaries was replaced by CSL; since then the German subsidiary has been operating as CSL Behring GmbH .

Today (May 2019) around 2,900 employees work at the Marburg location, which makes it the largest research and production location of the CSL Group. Another location in Germany is in Hattersheim near Frankfurt, where the sales department is located.

In the financial year from July 1, 2016 to June 30, 2017, CSL Behring GmbH, based in Marburg , achieved sales of 1.958 billion euros according to the annual financial statements published in the Federal Gazette and transferred around 674 million euros in accordance with the profit transfer agreement .

In addition, several donation centers throughout Germany, a central laboratory in Göttingen and a central warehouse in Schwalmstadt are operated by the CSL Plasma company to ensure the supply of plasma . Plans and preparations (e.g. purchase of land) are currently underway for the relocation of the central warehouse to Lahntal - Goßfelden just a few kilometers from the Marburg production site.

Because of the production of blood coagulation factor VIII and Von Willebrand factor , CSL Behring was considered an essential facility for the USA in 2008.

In early April 2019 also known, that CSL Behring for at least two years as a main sponsor of the GFL -Footballteams Marburg Mercenaries hired

CSL Behring AG (Switzerland)

Today's Swiss subsidiary was founded in 1949 by the Swiss Red Cross (SRK) as the central laboratory for the blood donation service SRK (ZLB) in Bern. In 1951 the ZLB was allowed by the federal government to manufacture and sell drugs from blood plasma.

In 2000, the CSL-Holding took over the central laboratory blood donation service from the Red Cross and founded the ZLB Bioplasma in the form of a stock corporation under Swiss law . In 2001, CSL Holding took over Plasma Laboratories in the USA, which also had the abbreviation ZLB as part of the company name ZLB Plasma Services .

In 2004, the CSL Holding took over the pharmaceutical company Aventis Behring, which was merged with ZLB Bioplasma to form ZLB Behring. At the end of 2006, the acronym ZLB was replaced by CSL in the names of the subsidiaries. Since then, the Swiss subsidiary has operated as CSL Behring AG .

CSL employs around 1,592 people in the city of Bern and around 219 in Lengnau BE .

Web links

Individual evidence

  1. ↑ CSL Behring: CSL Behring Fact Sheet. Accessed October 9, 2019 (German).
  2. ↑ Michael Acker: CSL Behring presents record numbers; in Oberhessische Presse , August 20, 2009, p. 25.
  3. ↑ CSL Behring - well equipped for the future. In: Experience Behringwerke. Pharmaserv GmbH, accessed on May 12, 2019 .
  4. ↑ locations. CSL Behring, accessed on May 12, 2019 (company information, not a neutral source).
  5. ↑ Plasma Center. CSL Plasma, accessed May 12, 2019 (company information).
  6. ↑ Freya Altmüller: "Unique opportunity for Lahntal". Oberhessische Presse, October 27, 2017, accessed on May 12, 2019 .
  7. ↑ Tobias Kunz: CSL and Lahntal have signed a contract. June 12, 2018, accessed May 12, 2019 .
  8. ^ List of the Critical Foreign Dependencies Initiative
  9. ↑ Sebastian Leis- www.redvisionmedia.com: April 25, 2019: CSL Behring new sponsor of the Marburg Mercenaries. April 2, 2019, accessed May 12, 2019 .
  10. ↑ Julian Witschi: CSL Behring moves into the Stade de Suisse. In: bernerzeitung.ch . February 14, 2019, accessed February 24, 2019 .